These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Inhibition of copper transporter 1 prevents α-synuclein pathology and alleviates nigrostriatal degeneration in AAV-based mouse model of Parkinson's disease. Gou DH; Huang TT; Li W; Gao XD; Haikal C; Wang XH; Song DY; Liang X; Zhu L; Tang Y; Ding C; Li JY Redox Biol; 2021 Jan; 38():101795. PubMed ID: 33232911 [TBL] [Abstract][Full Text] [Related]
23. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies. Kawahata I; Finkelstein DI; Fukunaga K Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892 [TBL] [Abstract][Full Text] [Related]
24. Alpha Synuclein: Neurodegeneration and Inflammation. Forloni G Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982988 [TBL] [Abstract][Full Text] [Related]
25. Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease. Calabresi P; Di Lazzaro G; Marino G; Campanelli F; Ghiglieri V Brain; 2023 Sep; 146(9):3587-3597. PubMed ID: 37183455 [TBL] [Abstract][Full Text] [Related]
26. Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function. Creed RB; Memon AA; Komaragiri SP; Barodia SK; Goldberg MS Acta Neuropathol Commun; 2022 May; 10(1):78. PubMed ID: 35606853 [TBL] [Abstract][Full Text] [Related]
27. The relation between α-synuclein and microglia in Parkinson's disease: Recent developments. Sanchez-Guajardo V; Tentillier N; Romero-Ramos M Neuroscience; 2015 Aug; 302():47-58. PubMed ID: 25684748 [TBL] [Abstract][Full Text] [Related]
28. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. Vekrellis K; Stefanis L Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256 [TBL] [Abstract][Full Text] [Related]
29. Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease. Bartl M; Xylaki M; Bähr M; Weber S; Trenkwalder C; Mollenhauer B Neurobiol Dis; 2022 Aug; 170():105744. PubMed ID: 35513230 [TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation. George S; Brundin P J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122 [TBL] [Abstract][Full Text] [Related]
31. Neuropathology and molecular diagnosis of Synucleinopathies. Koga S; Sekiya H; Kondru N; Ross OA; Dickson DW Mol Neurodegener; 2021 Dec; 16(1):83. PubMed ID: 34922583 [TBL] [Abstract][Full Text] [Related]
32. Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies. Terkelsen MH; Klaestrup IH; Hvingelby V; Lauritsen J; Pavese N; Romero-Ramos M J Parkinsons Dis; 2022; 12(s1):S149-S163. PubMed ID: 35723115 [TBL] [Abstract][Full Text] [Related]
33. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Fellner L; Jellinger KA; Wenning GK; Stefanova N Acta Neuropathol; 2011 Jun; 121(6):675-93. PubMed ID: 21562886 [TBL] [Abstract][Full Text] [Related]
34. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. Henderson MX; Trojanowski JQ; Lee VM Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426 [TBL] [Abstract][Full Text] [Related]
35. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. Benskey MJ; Perez RG; Manfredsson FP J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372 [TBL] [Abstract][Full Text] [Related]
36. From the Gut to the Brain: The Role of Enteric Glial Cells and Their Involvement in the Pathogenesis of Parkinson's Disease. Montalbán-Rodríguez A; Abalo R; López-Gómez L Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279293 [TBL] [Abstract][Full Text] [Related]
37. Immunoregulation of microglial polarization: an unrecognized physiological function of α-synuclein. Li N; Stewart T; Sheng L; Shi M; Cilento EM; Wu Y; Hong JS; Zhang J J Neuroinflammation; 2020 Sep; 17(1):272. PubMed ID: 32943057 [TBL] [Abstract][Full Text] [Related]
38. Initiation and progression of α-synuclein pathology in Parkinson's disease. Tofaris GK Cell Mol Life Sci; 2022 Mar; 79(4):210. PubMed ID: 35347432 [TBL] [Abstract][Full Text] [Related]
39. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432 [TBL] [Abstract][Full Text] [Related]
40. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy. Schaser AJ; Stackhouse TL; Weston LJ; Kerstein PC; Osterberg VR; López CS; Dickson DW; Luk KC; Meshul CK; Woltjer RL; Unni VK Acta Neuropathol Commun; 2020 Aug; 8(1):150. PubMed ID: 32859276 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]